Advancing HIV-1 Vaccine Design: Understanding the Connection Between HIV-1 Viral Envelope and the Induced Neutralizing Antibody Response, and the Development of an Alphavirus based HIV-1 Vaccine Vector
Abstract
Induction of potent, broadly cross-reactive neutralizing antibodies (bcnAbs) remains a primary goal in HIV-1 vaccine development. Human clinical trials of HIV-1 vaccines have been largely unsuccessful until recently, when the RV144 Thai vaccine study demonstrated modest efficacy in preventing the acquisition of virus. These trials have highlighted the complexities of designing and delivering an immunogen capable of eliciting a humoral and/or cell mediated immune response. We investigated both of these aspects of vaccine design, beginning with a focus on screening for HIV-1 infected individuals who develop bcnAbs, and looking for connections between the envelope glycoprotein from early infection and the induced neutralizing antibody response. We also developed a potential replication competent HIV-1 vaccine vector based on the alphavirus, Fort Morgan Virus, and tested its safety and immunogenicity in a small animal pilot study.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 18, 2014
- Accession Number
- AD1127741
Entities
People
- David Chang
Organizations
- Uniformed Services University of the Health Sciences